Compare Arista Networks Inc (ANET) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arista Networks Inc vs Merck & Co., Inc. — how do they compare? Arista Networks Inc trades at $187.83 (market cap $235.41B), while Merck & Co., Inc. trades at $124.37 (market cap $305.12B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.75% dividend while Arista Networks Inc pays none. Which is the better fit depends on your goals.
| ANET | MRK | |
|---|---|---|
Market Cap | $235.41B | $305.12B |
Sector | Technology | Health |
52-Week High | $186.96 | $129.52 |
52-Week Low | $107.37 | $77.60 |
Enterprise Value | $223.06B | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Arista Networks (ANET) trades at $186.96, up 1.23% with strong technical momentum as price approaches resistance at $189. The company demonstrates robust fundamentals with 2025 revenue of $9.01B and net income of $3.51B (38.32% margin), though valuation metrics remain elevated with P/E of 64.25. Recent earnings beats and AI infrastructure tailwinds support positive sentiment.
Arista presents growth potential from AI networking demand with 75% analyst buy ratings and $192.82 consensus target, but faces risks from high valuation multiples and competitive pressures. The stock's technical setup suggests near-term resistance testing with support at $180, while fundamental strength supports long-term growth outlook.
Merck (MRK) trades at $123.54, down 1.22% today, with a bullish technical signal from moving averages and a consensus analyst price target of $135.14. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of -$1.28 beating expectations. Revenue grew to $65.01B in 2025, and net income reached $18.25B, reflecting a robust 28.07% profit margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives.
The outlook for MRK remains positive driven by earnings momentum and strategic acquisitions, though risks include rising debt levels and competitive pressures. Wall Street sentiment is bullish with 68% buy ratings, but investors should monitor execution of the Terns integration and patent expirations. The stock offers potential upside to the price target with solid fundamentals supporting long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arista Networks Inc
Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.
Read more on ANET →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
